Tag Archives: (OGN)

Even A Pig Could Make Money Here

I was camped out in Kyiv the other month when news of Organon’s (OGN) earnings hit my phone. While Russian drones buzzed overhead, I was studying pharmaceutical balance sheets—talk about surreal. Did I mention I’ve led a strange life? In mid-February, Organon pleasantly surprised me with Q4 2024 results. Hadlima, their biosimilar to Humira, rocketed […]